| symbol | PVT1 |
| name | Pvt1 oncogene (non-protein coding) |
| location | 8q24.21 |
| alias_symbol | NCRNA00079|LINC00079|onco-lncRNA-100 |
| alias_name | non-protein coding RNA 79|long intergenic non-protein coding RNA 79 |
| Tissue | bladder,bone marrow,breast,cervix,colorectum,kidney,liver,lung,ovary,pancreas,pleura,stomach,thyroid, |
| Cancer | acute promyelocytic leukemia,bladder cancer,breast cancer,cervical cancer,colorectal cancer,gastric cancer,hepatic cancer,malignant pleural mesothelioma,non-small-cell lung cancer,ovarian cancer,pancreatic cancer,renal cancer,thyroid cancer, |
LncRNA PVT1 is higher in acute promyelocytic leukemia (APL) (1), malignant pleural mesothelioma (2), non-small cell lung cancer (NSCLC) (3), breast cancer (4), ovarian cancer (5), cervical cancer（6）, gastric cancer (7), pancreatic cancer (8), colorectal cancer (9), bladder cancer (10) and renal carcinoma (11). PVT1 expression level is associated with clinicopathological parameters such as lymph node metastasis, TNM stage, prognosis etc. (7, 3). Functionally, PVT1 regulates cancer cell proliferation, migration, metastasis, invasion, apoptosis and EMT (6, 3). At molecular level, PVT1 can bind to EZH2 (12). Moreover, PVT1 negatively regulates miR-200b (12), p15, p16 (7), TGF-β1, p-Smad4, Caspase-3 (13), TSHR (14), LATS2 (15) and positively regulate myc (11).
| LncRNA | tissue | cancer type | expression level | oncogene/suppress gene | pathway | binding gene/factor | associated gene/factor | proliferation | apoptosis | migration | EMT | invasion | metastasis | prognosis | tag | PMID | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | PVT1 | colorectum | colorectal cancer | up | onco | + | - | - | 24196785 | ||||||||
| 1 | PVT1 | breast | breast cancer | / | / | SNP | 24780616 | ||||||||||
| 2 | PVT1 | pleura | malignant pleural mesothelioma | up | / | caspase-3-,C-MYC+ | - | 24926545 | |||||||||
| 3 | PVT1 | liver | hepatic cancer | up | onco | NOP2+ | cell cycle genes | + | - | cancer stem cells | 25043274 | ||||||
| 4 | PVT1 | stomach | gastric cancer | up | / | 25258543 | |||||||||||
| 5 | PVT1 | lung | non-small-cell lung cancer | up | onco | + | + | + | - | 25400777 | |||||||
| 6 | PVT1 | liver | hepatic cancer | up | / | - | 25624916 | ||||||||||
| 7 | PVT1 | pancreas | pancreatic cancer | up | / | - | 25668599 | ||||||||||
| 8 | PVT1 | stomach | gastric cancer | up | onco | EZH2+ | p15- p16- | + | + | - | 25890171 | ||||||
| 9 | PVT1 | stomach | gastric cancer | up | onco | MDR1+,MRP+,mTOR+,HIF-1α+ | - | chemotherapy resistance | 25956062 | ||||||||
| 10 | PVT1 | ovary | ovarian cancer | up | onco | p53-,TIMP1- | + | chemotherapy resistance | 26097562 | ||||||||
| 11 | PVT1 | thyroid | thyroid cancer | up | onco | EZH2 | TSHR- | + | 26427660 | ||||||||
| 12 | PVT1 | bladder | bladder cancer | up | onco | + | - | chemotherapy resistance | 26517688 | ||||||||
| 13 | PVT1 | bone marrow | acute promyelocytic leukemia | up | onco | +MYC | + | 26545364 | |||||||||
| 14 | PVT1 | ovary | ovarian cancer | up | onco | TGF-β1-,p-Smad4-,caspase-3- | - | chemotherapy resistance | 26884974 | ||||||||
| 15 | PVT1 | lung | non-small-cell lung cancer | up | onco | Mdm2-p53， | EZH2 | LATS2- | + | - | - | 26908628 | |||||
| 16 | PVT1 | stomach | gastric cancer | up | onco | - | 26925791 | ||||||||||
| 17 | PVT1 | cervix | cervical cancer | up | onco | + | - | + | + | - | chemotherapy resistance | 27232880 | |||||
| 18 | PVT1 | cervix | cervical cancer | up | onco | EZH2 | miR-200b- | + | + | - | 27272214 | ||||||
| 19 | PVT1 | kidney | renal cancer | up | / | MYC+ | - | CNV | 27366943 |
Expression profile in human body map
Expression profile in TCGA
| entrez_id | 5820 |
| ucsc_id | uc003ysl.4 |
| Ensembl_gene_id | ENSG00000249859 |
| HGNC_id | HGNC:9709 |
| Omim_id | 165140 |
| cosmic | |
| lncrnadb | pvt1 |
[1]. Zeng C, Yu X, Lai J, Yang L, Chen S, et al. (2015). Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol 8: 126. link pubmed
[2]. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, et al. (2014). Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 9(7): 998-1007. link pubmed
[3]. Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS, et al. (2014). Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol 7(10): 6929-35. link pubmed
[4]. Zhang Z, Zhu Z, Zhang B, Li W, Li X, et al. (2014). Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer. J Genet Genomics 41(4): 187-95. link pubmed
[5]. Liu E, Liu Z, Zhou Y (2015). Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol 8(4): 3803-10. link pubmed
[6]. Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, et al. (2016). The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One 11(5): e0156274. link pubmed
[7]. Kong R, Zhang EB, Yin DD, You LH, Xu TP, et al. (2015). Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 14: 82. link pubmed
[8]. Xie Z, Chen X, Li J, Guo Y, Li H, et al. (2016). Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer. Oncotarget 7(18): 25408-19. link pubmed
[9]. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, et al. (2014). Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 110(1): 164-71. link pubmed
[10]. Zhuang C, Li J, Liu Y, Chen M, Yuan J, et al. (2015). Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget 6(38): 41194-203. link pubmed
[11]. Posa I, Carvalho S, Tavares J, Grosso AR (2016). A pan-cancer analysis of MYC-PVT1 reveals CNV-unmediated deregulation and poor prognosis in renal carcinoma. Oncotarget 7(30): 47033-47041. link pubmed
[12]. Zhang S, Zhang G, Liu J (2016). Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b. APMIS 124(8): 649-58. link pubmed
[13]. Liu E, Liu Z, Zhou Y, Mi R, Wang D (2015). Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med 8(11): 20565-72. link pubmed
[14]. Zhou Q, Chen J, Feng J, Wang J (2016). Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol 37(3): 3105-13. link pubmed
[15]. Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, et al. (2016). Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression. Mol Cancer Ther 15(5): 1082-94. link pubmed